Abstract:
:We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 84 induction but relapsed during consolidation therapy or after completing the whole programme. Twenty-three patients were evaluable for response. The VIM regimen provided a 43 per cent complete response rate and an additional 17 per cent partial response rate. The complete response rate was particularly high (67 per cent) in the group of patients who were partial responders to LNH 84 induction treatment. Of the 10 complete responders, five relapsed after 4 to 42 months and five are still alive with no evidence of disease after 27 to 60 months. Overall VIM was well tolerated. Myelotoxicity was the most common side-effect. Infections with fever were observed in 8 per cent of the VIM courses. This study demonstrates that a complete response and a long survival can be obtained in patients after failure of a high-dose doxorubicin containing front-line treatment.
journal_name
Hematol Oncoljournal_title
Hematological oncologyauthors
Herbrecht R,Ortiz S,Damonte JC,Liu KL,Maloisel F,Dufour P,Bergerat JP,Oberling Fdoi
10.1002/hon.2900090411subject
Has Abstractpub_date
1991-07-01 00:00:00pages
253-7issue
4-5eissn
0278-0232issn
1099-1069journal_volume
9pub_type
临床试验,杂志文章,多中心研究abstract::The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers,...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2547
更新日期:2019-02-01 00:00:00
abstract::Ten patients with the myelodysplastic syndrome (eight with anemia, two with granulocytopenia, four with thrombocytopenia) were given etretinate (ER) and retinoid acid (RA). No correlation was seen between the RA effect in vitro and its clinical effect. No effect was seen of the ER-treatment or of the RA-treatment on a...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070407
更新日期:1989-07-01 00:00:00
abstract::Composite plasma cell neoplasm (PCN) and low grade B-cell lymphoma (B-NHL) in the bone marrow are uncommon and raise the differential diagnosis of B-NHL with plasmacytic differentiation and PCN with lymphoplasmacytic morphology. This can be a challenging differential diagnosis, and the distinctions are important becau...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2129
更新日期:2015-03-01 00:00:00
abstract::Primary bone marrow lymphoma is a rare disease and remains undiagnosed due to deceptive clinical presentation. Here, we report four cases of primary bone marrow B-cell non-Hodgkin lymphoma, which presented with cytopenias without any lymphadenopathy or organomegaly. Bone marrow examination revealed large atypical B-ce...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2178
更新日期:2016-03-01 00:00:00
abstract::Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2162
更新日期:2016-03-01 00:00:00
abstract::Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2344
更新日期:2017-12-01 00:00:00
abstract::We compare 30 biopsies each of Pattern 1 angioimmunoblastic T-cell lymphoma (AITL1) and reactive lymphoid hyperplasia (RLH) by immunohistology, in-situ hybridization for Epstein-Barr virus-encoded RNA and T-cell receptor-γ (TRG)-clonality. AITL1 cases, more often than RLH controls, were older [median ages 61 (range 23...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2116
更新日期:2014-09-01 00:00:00
abstract::This report summarizes a closed workshop cosponsored by the American Association for Cancer Research, the European School of Oncology, and the 15th-International Conference on Malignant Lymphoma to discuss critical open questions on liquid biopsy in lymphoid malignancies, develops a roadmap for their analytical and cl...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2704
更新日期:2020-02-01 00:00:00
abstract::The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/(sici)1099-1069(199702)15:1<3::aid-hon583>
更新日期:1997-02-01 00:00:00
abstract::Peripheral blood progenitor cells used during high dose treatments for malignancy may be contaminated with tumour cells that could later contribute to recurrence. CD34+ selected harvests still contain tumour cells and an additional negative selection may be capable of reducing this contamination. We have assessed a tw...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/1099-1069(200009)18:3<111::aid-hon657>3.0.
更新日期:2000-09-01 00:00:00
abstract::Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2772
更新日期:2020-10-01 00:00:00
abstract::Fungal infection is a serious complication in immunocompromised patients, especially those with neutropenia. Itraconazole (ITZ) is expected to be an effective prophylactic agent for fungal infection because it has more activity against Aspergillus species than fluconazole and it is less toxic than amphotericin-B. Howe...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/(sici)1099-1069(1998030)16:1<33::aid-hon62
更新日期:1998-03-01 00:00:00
abstract::One hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty-seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate. ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900080103
更新日期:1990-01-01 00:00:00
abstract::Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL tra...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.792
更新日期:2006-12-01 00:00:00
abstract::Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2532
更新日期:2018-10-01 00:00:00
abstract::Mucosa-associated lymphatic tissue (MALT) lymphoma of the breast is an extremely rare disease; its pathogenesis is not clear because of the rarity of disease, and the best diagnostic method has yet to be established. The metabolic behavior of this lymphoma is not still clear because only a few case reports are present...
journal_title:Hematological oncology
pub_type:
doi:10.1002/hon.2376
更新日期:2017-12-01 00:00:00
abstract::Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2205
更新日期:2016-12-01 00:00:00
abstract::Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900120104
更新日期:1994-01-01 00:00:00
abstract::This paper presents a new analysis of aspects of the descriptive epidemiology of multiple myeloma (MM) for parts of the U.K., 1984-1993. It provides no indication for geographical heterogeneity, nor is there evidence of a decline in rates over the decade. There is, however, evidence that cancer registration inflates M...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/(sici)1099-1069(199903)17:1<31::aid-hon636
更新日期:1999-03-01 00:00:00
abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析,评审
doi:10.1002/hon.2152
更新日期:2015-09-01 00:00:00
abstract::Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2711
更新日期:2020-08-01 00:00:00
abstract::The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2646
更新日期:2019-10-01 00:00:00
abstract::Multiple myeloma, which is a monoclonal plasma cell malignancy, still remains incurable despite recent progress in our understanding of this disorder. Adoptive immunotherapy of multiple myeloma using cytokine-induced killer cells is yielding promising results in clinical trials; however, some myeloma cells still evade...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2326
更新日期:2017-12-01 00:00:00
abstract::The REAL Classification of lymphomas, proposed in 1994, represents a new paradigm in lymphoma classification, consisting of a list of biologic entities defined by clinicopathologic and immunogenetic features. The non-Hodgkin's lymphomas comprise precursor lymphoblastic and mature cell neoplasms of B, T or putative nat...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.660
更新日期:2001-12-01 00:00:00
abstract::The management of patients with follicular lymphoma is controversial, particularly in those with follicular small cleaved cell (FSCC) or nodular poorly differentiated lymphoma (NPDL). Some advocate no treatment until symptoms arise, while others prefer to treat with intensive combination regimens and others with singl...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900050207
更新日期:1987-04-01 00:00:00
abstract::Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overa...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2522
更新日期:2018-12-01 00:00:00
abstract::The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alterations on chromoso...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/(sici)1099-1069(199708)15:3<109::aid-hon60
更新日期:1997-08-01 00:00:00
abstract::One hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The younger patients, at or below the age o...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2900110106
更新日期:1993-01-01 00:00:00
abstract::We verified whether early resistance to treatment can be predicted in a subset of patients with very favourable, early stage Hodgkin lymphoma, treated with VBM (vinblastine, bleomycin and methotrexate) chemotherapy and involved-field radiotherapy, an effective combination with very low early and late toxicity. The rel...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2035
更新日期:2013-09-01 00:00:00
abstract::Mucosa-associated lymphoid tissue (MALT) lymphoma is a radiosensitive malignancy. We report on a case of severe retinopathy following radiation therapy with a moderate dose for orbital MALT lymphoma. A 69-year-old woman with orbital MALT lymphoma received definitive radiation therapy with a total dose of 36 Gy in 18 f...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2124
更新日期:2014-12-01 00:00:00